{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:34Z","timestamp":1794255874900,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg","id":[{"id":"https:\/\/ror.org\/03pvr2g57","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03718-w","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:25:25Z","timestamp":1787369125000},"page":"4981-4992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Experience of Adrenocortical Carcinoma: Views from a Patient, His Physician and a Patient Association"],"prefix":"10.1007","volume":"43","author":[{"given":"Marc","family":"B\u00fcdenbender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Heitz-Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":false,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"3718_CR1","doi-asserted-by":"publisher","first-page":"bvae012","DOI":"10.1210\/jendso\/bvae012","volume":"8","author":"J Pedersen","year":"2003","unstructured":"Pedersen J, Jarl\u00f8v AE, Rasmussen \u00c5K, Stochholm K. Incidence, treatment, and survival of adrenocortical carcinoma in Denmark 2003\u20132019. J Endocr Soc. 2003;8:bvae012.","journal-title":"J Endocr Soc"},{"key":"3718_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","volume":"13","author":"M Fassnacht","year":"2025","unstructured":"Fassnacht M, Puglisi S, Kimpel O, Terzolo M. Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diabetes Endocrinol. 2025;13:438\u201352.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3718_CR3","unstructured":"Maruf N, Bohra AS. Enhancing recruitment and retention in rare diseases trials. 2016. Orphan Reach. https:\/\/orphan-reach.com\/wp-content\/uploads\/2016\/09\/Enhancing_recruitment_and_retention_in_rare_disease_trials.pdf. Accessed 3 March 2026."},{"key":"3718_CR4","doi-asserted-by":"publisher","first-page":"znae177","DOI":"10.1093\/bjs\/znae177","volume":"111","author":"C de Ponthaud","year":"2024","unstructured":"de Ponthaud C, Roy M, Gaujoux S. Adrenocortical carcinoma: what you at least should know. Br J Surg. 2024;111:znae177.","journal-title":"Br J Surg"},{"key":"3718_CR5","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1-46.","journal-title":"Eur J Endocrinol"},{"key":"3718_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ecl.2018.02.003","volume":"47","author":"S Puglisi","year":"2018","unstructured":"Puglisi S, Perotti P, Pia A, Reimondo G, Terzolo M. Adrenocortical carcinoma with hypercortisolism. Endocrinol Metab Clin N Am. 2018;47:395\u2013407.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3718_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s11154-025-09989-y","volume":"26","author":"V Guarnotta","year":"2025","unstructured":"Guarnotta V, Stigliano A, Terzolo M, Arnaldi G. Management of Cushing\u2019s syndrome in patients with adrenocortical cancer: state of the art and future perspectives. Rev Endocr Metab Disord. 2025;26:1023\u201335.","journal-title":"Rev Endocr Metab Disord"},{"key":"3718_CR8","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1210\/clinem\/dgad453","volume":"109","author":"S Puglisi","year":"2024","unstructured":"Puglisi S, Perini AME, Botto C, Oliva F, Terzolo M. Long-term consequences of Cushing syndrome: a systematic literature review. J Clin Endocrinol Metab. 2024;109:e901\u201319.","journal-title":"J Clin Endocrinol Metab"},{"key":"3718_CR9","doi-asserted-by":"publisher","first-page":"105562","DOI":"10.1016\/j.nurpra.2025.105562","volume":"22","author":"R Ray","year":"2026","unstructured":"Ray R, Cruse DR. Should hypercortisolism be part of your differential diagnosis? J Nurse Pract. 2026;22:105562.","journal-title":"J Nurse Pract"},{"key":"3718_CR10","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/jamaoncol.2019.1558","volume":"5","author":"G Assi\u00e9","year":"2019","unstructured":"Assi\u00e9 G, Jouinot A, Fassnacht M, et al. Value of molecular classification for prognostic assessment of adrenocortical carcinoma. JAMA Oncol. 2019;5:1440\u20137.","journal-title":"JAMA Oncol"},{"key":"3718_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","volume":"46","author":"G Assi\u00e9","year":"2014","unstructured":"Assi\u00e9 G, Letouz\u00e9 E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607\u201312.","journal-title":"Nat Genet"},{"key":"3718_CR12","doi-asserted-by":"publisher","first-page":"112272","DOI":"10.1016\/j.mce.2024.112272","volume":"590","author":"DS Tourigny","year":"2024","unstructured":"Tourigny DS, Altieri B, Secener KA, et al. Cellular landscape of adrenocortical carcinoma at single-nuclei resolution. Mol Cell Endocrinol. 2024;590:112272.","journal-title":"Mol Cell Endocrinol"},{"key":"3718_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723\u201336.","journal-title":"Cancer Cell"},{"key":"3718_CR14","doi-asserted-by":"publisher","first-page":"E493","DOI":"10.1210\/jc.2014-3282","volume":"100","author":"CC Juhlin","year":"2015","unstructured":"Juhlin CC, Goh G, Healy JM, et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab. 2015;100:E493\u2013502.","journal-title":"J Clin Endocrinol Metab"},{"key":"3718_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.surg.2015.08.038","volume":"159","author":"TC Brown","year":"2016","unstructured":"Brown TC, Juhlin CC, Healy JM, et al. DNA copy amplification and overexpression of SLC12A7 in adrenocortical carcinoma. Surgery. 2016;159:250\u20137.","journal-title":"Surgery"},{"key":"3718_CR16","doi-asserted-by":"publisher","first-page":"bvaa060","DOI":"10.1210\/jendso\/bvaa060","volume":"4","author":"TC Brown","year":"2020","unstructured":"Brown TC, Nicolson NG, Man J, et al. Recurrent amplification of the osmotic stress transcription factor NFAT5 in adrenocortical carcinoma. J Endocr Soc. 2020;4:bvaa060.","journal-title":"J Endocr Soc"},{"key":"3718_CR17","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.surg.2016.11.036","volume":"161","author":"TD Murtha","year":"2017","unstructured":"Murtha TD, Brown TC, Rubinstein JC, et al. Overexpression of cytochrome P450 2A6 in adrenocortical carcinoma. Surgery. 2017;161:1667\u201374.","journal-title":"Surgery"},{"key":"3718_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.surg.2015.09.001","volume":"159","author":"JC Rubinstein","year":"2016","unstructured":"Rubinstein JC, Brown TC, Goh G, et al. Chromosome 19 amplification correlates with advanced disease in adrenocortical carcinoma. Surgery. 2016;159:296\u2013301.","journal-title":"Surgery"},{"key":"3718_CR19","doi-asserted-by":"publisher","first-page":"103617","DOI":"10.1016\/j.esmoop.2024.103617","volume":"9","author":"A Sun-Zhang","year":"2024","unstructured":"Sun-Zhang A, Juhlin CC, Carling T, et al. Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival. ESMO Open. 2024;9:103617.","journal-title":"ESMO Open"},{"key":"3718_CR20","first-page":"1675","volume":"42","author":"F Svahn","year":"2018","unstructured":"Svahn F, Paulsson JO, Stenman A, et al. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma. Int J Mol Med. 2018;42:1675\u201383.","journal-title":"Int J Mol Med"},{"key":"3718_CR21","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189\u201397.","journal-title":"N Engl J Med"},{"key":"3718_CR22","unstructured":"United States Food and Drug Administration. Lysodren\u00ae (mitotane) tablets, for oral use [prescribing information]. 1970. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/016885s033lbl.pdf. Accessed 3 March 2026."},{"key":"3718_CR23","unstructured":"European Medicines Agency. Lysodren (mitotane): EPAR\u2014product information [summary of product characteristics]. 2009. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lysodren-epar-product-information_en.pdf. Accessed 3 March 2026."},{"key":"3718_CR24","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1210\/jc.2019-00600","volume":"104","author":"BA Carneiro","year":"2019","unstructured":"Carneiro BA, Konda B, Costa RB, et al. Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. J Clin Endocrinol Metab. 2019;104:6193\u2013200.","journal-title":"J Clin Endocrinol Metab"},{"key":"3718_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","volume":"6","author":"C Le Tourneau","year":"2018","unstructured":"Le Tourneau C, Hoimes C, Zarwan C, et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018;6:111.","journal-title":"J Immunother Cancer"},{"key":"3718_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","volume":"7","author":"MA Habra","year":"2019","unstructured":"Habra MA, Stephen B, Campbell M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019;7:253.","journal-title":"J Immunother Cancer"},{"key":"3718_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.19.01586","volume":"38","author":"N Raj","year":"2020","unstructured":"Raj N, Zheng Y, Kelly V, et al. PD-1 blockade in advanced adrenocortical carcinoma. J Clin Oncol. 2020;38:71\u201380.","journal-title":"J Clin Oncol"},{"key":"3718_CR28","doi-asserted-by":"publisher","first-page":"10371","DOI":"10.1038\/s41467-024-54661-9","volume":"15","author":"YC Zhu","year":"2024","unstructured":"Zhu YC, Wei ZG, Wang JJ, et al. Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial. Nat Commun. 2024;15:10371.","journal-title":"Nat Commun"},{"key":"3718_CR29","first-page":"635","volume":"6","author":"AR Glover","year":"2013","unstructured":"Glover AR, Ip JC, Zhao JT, Soon PS, Robinson BG, Sidhu SB. Current management options for recurrent adrenocortical carcinoma. Onco Targets Ther. 2013;6:635\u201343.","journal-title":"Onco Targets Ther"},{"key":"3718_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.eprac.2024.11.007","volume":"31","author":"X Wang","year":"2025","unstructured":"Wang X, Li J, Zhang Y, Huang R, Zhang P, Hu H. Comprehensive analysis of mitotane-related adverse events using the Food and Drug Administration Adverse Event Reporting System. Endocr Pract. 2025;31:278\u201385.","journal-title":"Endocr Pract"},{"key":"3718_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1530\/EJE-11-0557","volume":"166","author":"S Maucl\u00e8re-Denost","year":"2012","unstructured":"Maucl\u00e8re-Denost S, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol. 2012;166:261\u20138.","journal-title":"Eur J Endocrinol"},{"key":"3718_CR32","first-page":"2234","volume":"85","author":"M Terzolo","year":"2000","unstructured":"Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab. 2000;85:2234\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"3718_CR33","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1210\/jc.2013-2281","volume":"98","author":"TM Kerkhofs","year":"2013","unstructured":"Kerkhofs TM, Baudin E, Terzolo M, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4759\u201367.","journal-title":"J Clin Endocrinol Metab"},{"key":"3718_CR34","first-page":"100759","volume":"37","author":"R Lib\u00e9","year":"2023","unstructured":"Lib\u00e9 R, Huillard O. Adrenocortical carcinoma: diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun. 2023;37:100759.","journal-title":"Cancer Treat Res Commun"},{"key":"3718_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cen.13302","volume":"86","author":"M Weigel","year":"2017","unstructured":"Weigel M, Hahner S, Sherlock M, et al. Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer. Clin Endocrinol (Oxf). 2017;86:499\u2013505.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3718_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ejendo\/lvae007","volume":"190","author":"B Altieri","year":"2024","unstructured":"Altieri B, Kimpel O, Megerle F, et al. Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma. Eur J Endocrinol. 2024;190:139\u201350.","journal-title":"Eur J Endocrinol"},{"key":"3718_CR37","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.jcpo.2026.100704","volume":"47","author":"RJ Crowley","year":"2026","unstructured":"Crowley RJ, Lally JS, Kline DM, Bunting AM. Geographic disparities in access to oncologists and association with cancer outcomes in the United States. J Cancer Policy. 2026;47:100704.","journal-title":"J Cancer Policy"},{"key":"3718_CR38","first-page":"101756","volume":"66","author":"A Ugalde","year":"2026","unstructured":"Ugalde A, Jongebloed H, Wright C, et al. Towards equitable cancer outcomes for rural and remote communities: reflections, lessons and recommendations. Lancet Reg Health West Pac. 2026;66:101756.","journal-title":"Lancet Reg Health West Pac"},{"key":"3718_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/curroncol32060349","volume":"32","author":"ZS Chin","year":"2025","unstructured":"Chin ZS, Ghodrati A, Foulger M, Demirkhanyan L, Gondi CS. Beyond barriers: achieving true equity in cancer care. Curr Oncol. 2025;32:349.","journal-title":"Curr Oncol"},{"key":"3718_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13023-025-03818-w","volume":"20","author":"S Briscoe","year":"2025","unstructured":"Briscoe S, Martin Pintado C, Sutcliffe K, et al. Evidence of inequities experienced by the rare disease community with respect to receipt of a diagnosis and access to services: a scoping review of UK and international evidence. Orphanet J Rare Dis. 2025;20:303.","journal-title":"Orphanet J Rare Dis"},{"key":"3718_CR41","first-page":"OC6.4","volume":"90","author":"MP Schauer","year":"2023","unstructured":"Schauer MP, Landwehr LS, Justus W, et al. CAR-T cell therapy exerts antitumor efficacy under immunosuppressive conditions in adrenocortical carcinoma [ECE2023 abstract]. Endocr Abstr. 2023;90:OC6.4.","journal-title":"Endocr Abstr"},{"key":"3718_CR42","unstructured":"Schauer MP, Weber J, Spieler P, et al. Autocrine signaling in hormonally active cancer induces antigen expression for immunotherapy [preprint]. bioRxiv 2025.01.28.632923."},{"key":"3718_CR43","doi-asserted-by":"publisher","first-page":"S520","DOI":"10.1016\/j.annonc.2024.08.727","volume":"35","author":"BJ Sikkema","year":"2024","unstructured":"Sikkema BJ, Champiat S, Gort EH, et al. 661P Safety and activity of CY-101 in patients with advanced solid tumors: the phase I\/IIa CICILIA trial [ESMO abstract]. Ann Oncol. 2024;35:S520\u20131.","journal-title":"Ann Oncol"},{"key":"3718_CR44","unstructured":"Let\u2019s Cure ACC. http:\/\/letscureacc.com\/. Accessed 9 June 2026."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03718-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03718-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03718-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:10Z","timestamp":1794254590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03718-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3718"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03718-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marc B\u00fcdenbender, Catherine Heitz-Lamy, and Martin Fassnacht declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on the experience of the authors (a patient, his physician, and a patient representative) and literature from previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The patient has consented to publication of this report.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}